MS

Matthew Szot

Chief Financial Officer and Co-Founder

Cadrenal Therapeutics

Cadrenal Therapeutics Pipeline

DrugIndicationPhase
CAD-1005Heparin-Induced Thrombocytopenia (HIT)Phase 3-ready
TecarfarinAnticoagulation in End-Stage Kidney Disease (ESKD) patients with Atrial Fibrillation (AF) and Patients with Left Ventricular Assist Devices (LVADs)Phase 3-ready
FrunexianAnticoagulation in acute/critical care hospital settings (e.g., complex cardiac surgery)Clinical-stage